UK Market Expands on Government-Backed Obesity and Diabetes Initiatives The UK GLP-1 receptor agonist market is projected to expand during the forecast period due to growing public health efforts to combat obesity and diabetes, supported by government-backed awareness campaigns and treatment guidelines
Sleep disorders in people with type 2 diabetes and associated health outcomes: a review of the literature
Weight loss reduces the mechanical load on bones, which can lead to lower bone density and, in some people such as those who are postmenopausal, as well as people over age 65 an increased risk of fracture
Clinical Pharmacology.] Use with Medications Known to Cause Hypoglycemia As is typical with other antihyperglycemic agents used in combination with a sulfonylurea, when Januvia was used in combination with a sulfonylurea, a class of medications known to cause hypoglycemia, the incidence of hypoglycemia was increased over that of placebo
We ask that patients go off their GLP-1s because they delay gastric emptying, meaning your stomach could still be full before your procedure, says Dr
Access to GLP-1 medications for weight management in the UK is governed by specific NICE Technology Appraisals and NHS commissioning policies, which establish strict eligibility criteria
